In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.
In REDEFINE 2, CagriSema reduced weight by 13.7% versus 3.4% with placebo at 68 weeks, and 73.5% achieved HbA1c <=6.5% in adults with type 2 diabetes.
A man who has been on the same small pill for nine years arrives to tell me he does not believe in it. A woman on three medications asks if she can stop the small one. Two composite vignettes from one fictional clinic morning.
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
A single-centre Egyptian RCT found the Diabetes Conversation Map programme improved diabetes knowledge, self-management, and self-efficacy questionnaire scores versus standard education (p < 0.001), with no clinical endpoints reported. PICO summary and expert commentary.
A post-hoc ACCORD-BP analysis of 307 patients with type 2 diabetes and prior stroke links intensive SBP control below 120 mmHg to lower MACE risk. PICO summary and expert commentary.
A randomised controlled trial of a psychosocial weight-management programme in overweight or obese pregnant women improved diet and activity but not gestational diabetes, preeclampsia, or caesarean rates. PICO summary and expert commentary.
A multicentre randomised trial testing a CBT-based WeChat dietary programme against standard care for postprandial glucose and pregnancy outcomes in gestational diabetes. PICO summary and expert commentary.
An EXSCEL post hoc simulation and mediation analysis showing conventional risk-factor changes explain only a modest share of once-weekly exenatide's cardiovascular effects. PICO summary and expert commentary.
A Brazilian randomized community trial reports preliminary reach and adherence for group-based nutrition interventions in primary care obesity management. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
